Utility of plasma circulating DNA tumor fraction in bone-only metastatic breast cancer: a real-world outcomes study
BO-MBC patients are as likely as non-BO-MBC to have detectable ctDNA and TF remains prognostic among BO-MBC patients, with TF < 1% associated with significantly better prognosis.
Authors
- Lincoln W. Pasquina (ORCID: https://orcid.org/0009-0009-5461-9777)
- Deloris J. Veney (ORCID: https://orcid.org/0000-0002-6730-3212)
- Ryon P. Graf (ORCID: https://orcid.org/0000-0002-8065-4148)
- Mia Levy (ORCID: https://orcid.org/0000-0002-5944-2730)
- Daniel G. Stover (ORCID: https://orcid.org/0000-0001-9003-8165)
- Júlia C.F. Quintanilha (ORCID: https://orcid.org/0000-0001-6908-4474)
- Gilbert Bader (ORCID: https://orcid.org/0000-0003-3576-7693)
Institutions
- Foundation Medicine (United States)
- The Ohio State University (US)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2025-05-30
- DOI
- https://doi.org/10.1007/s10549-025-07740-4
- Citations
- 3
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 2.81
Funders
- Susan G. Komen for the Cure
- Ohio State University
- Foundation Medicine